Investigational Drug Information for PF-07304814
✉ Email this page to a colleague
What is the development status for investigational drug PF-07304814?
PF-07304814 is an investigational drug.
There have been 5 clinical trials for PF-07304814.
The most recent clinical trial was a Phase 1 trial, which was initiated on August 4th 2020.
The most common disease conditions in clinical trials are COVID-19, Virus Diseases, and [disabled in preview]. The leading clinical trial sponsors are Pfizer, Prevention and Early Treatment of Acute Lung Injury (PETAL), and Cardiothoracic Surgical Trials Network (CTSN).
There are sixteen US patents protecting this investigational drug and forty-one international patents.
Summary for PF-07304814
| US Patents | 16 |
| International Patents | 41 |
| US Patent Applications | 62 |
| WIPO Patent Applications | 56 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 1 (2020-08-04) |
| Vendors | 25 |
Recent Clinical Trials for PF-07304814
| Title | Sponsor | Phase |
|---|---|---|
| Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]-PF-07304814 in Healthy Participants | Pfizer | Phase 1 |
| PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) | AIDS Clinical Trials Group | Phase 3 |
| PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) | Cardiothoracic Surgical Trials Network (CTSN) | Phase 3 |
Clinical Trial Summary for PF-07304814
Top disease conditions for PF-07304814
Top clinical trial sponsors for PF-07304814
US Patents for PF-07304814
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| PF-07304814 | ⤷ Start Trial | Niclosamide formulations for treating disease | Union Therapeutics AS | ⤷ Start Trial |
| PF-07304814 | ⤷ Start Trial | Vidofludimus for use in the treatment or prevention of viral diseases | Immunic AG | ⤷ Start Trial |
| PF-07304814 | ⤷ Start Trial | Triazine derivatives having virus replication inhibitory activity and pharmaceutical composition comprising the same | Hokkaido University NUC , Shionogi and Co Ltd | ⤷ Start Trial |
| PF-07304814 | ⤷ Start Trial | Methods for treating, ameliorating or preventing infections using drug and vaccination combination treatment | Topelia Aust Ltd Acn 652 771 670 , Topelia Aust Ltd 652 771 670 , Centre for Digestive Diseases Pty Ltd | ⤷ Start Trial |
| PF-07304814 | ⤷ Start Trial | Compositions and methods for inhibiting Mpro and PLpro protease activity and for preventing and treating SARS-CoV-2 infection | University of Arizona | ⤷ Start Trial |
| PF-07304814 | ⤷ Start Trial | Solid forms of emetine | Acer Therapeutics Inc | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for PF-07304814
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| PF-07304814 | Australia | AU2022204775 | 2041-04-14 | ⤷ Start Trial |
| PF-07304814 | Brazil | BR122023002208 | 2041-04-14 | ⤷ Start Trial |
| PF-07304814 | Canada | CA3195272 | 2041-04-14 | ⤷ Start Trial |
| PF-07304814 | Chile | CL2023003041 | 2041-04-14 | ⤷ Start Trial |
| PF-07304814 | China | CN115038696 | 2041-04-14 | ⤷ Start Trial |
| PF-07304814 | China | CN115073431 | 2041-04-14 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
